ENGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.578

+70.1%

-0.637

+32.64%

-0.648

+27.12%

Estimates Revision

The market is revising No Change the revenue expectations for enGene Holdings Inc. (ENGN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 41.96%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+41.96%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast ENGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENGN is 22.56 USD with a low forecast of 10.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 8.475

Low

10.00

Averages

22.56

High

33.00

Current: 8.475

Low

10.00

Averages

22.56

High

33.00

UBS

Neutral

maintain

$4 -> $10

2025-11-12

Reason

UBS

Price Target

$4 -> $10

2025-11-12

maintain

Neutral

Reason

UBS raised the firm's price target on enGene (ENGN) to $10 from $4 and keeps a Neutral rating on the shares. EnGene reported updated Phase 2 LEGEND trial data for detalimogene in high-risk BCG-unresponsive non-muscle invasive bladder cancer, showing a 63% anytime complete response rate and 62% six-month CR under the amended protocol, an improvement from prior results but below competitors CG Oncology (CGON) and Johnson & Johnson (JNJ), the analyst tells investors in a research note. While the results confirm deta's activity, limited near-term catalysts and a later market entry contribute to a Neutral outlook.

Oppenheimer

Outperform

maintain

$30 -> $33

2025-11-12

Reason

Oppenheimer

Price Target

$30 -> $33

2025-11-12

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on enGene to $33 from $30 and keeps an Outperform rating on the shares. The firm believes the reveal from the pivotal LEGEND trial in high-risk NMIBC is not only impressive in its own right - highlighted by detalimogene's 62% 6-month complete response rate - but also addresses the market's skepticism following last September's initial showing, which preceded changes that brought the trial's design closer to current standards for this indication.

Morgan Stanley

Overweight

maintain

$18 -> $19

2025-11-12

Reason

Morgan Stanley

Price Target

$18 -> $19

2025-11-12

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on enGene to $19 from $18 and keeps an Overweight rating on the shares after the company provided updated data from the pivotal cohort of its Phase 2 LEGEND trial, investigating its non-viral gene therapy detalimogene in Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer patients. Detalimogene's profile appears competitive with other NMIBC agents and 6-month CR was the "standout measure," says the analyst, who sees the update improving detalimogene's product profile.

Citizens JMP

Silvan Tuerkcan

Outperform

maintain

$18 -> $21

2025-11-12

Reason

Citizens JMP

Silvan Tuerkcan

Price Target

$18 -> $21

2025-11-12

maintain

Outperform

Reason

Citizens JMP analyst Silvan Tuerkcan raised the firm's price target on enGene to $21 from $18 and keeps an Outperform rating on the shares. Citizens was impressed by the speed of enrollment in enGene's LEGEND trial and the substantially higher complete response rate following protocol amendments that harmonized LEGEND with other newer non-muscle invasive bladder cancer assets, the analyst tells investors in a research note. EnGene has demonstrated that detalimogene is comparable to best-in-class assets on six-month CR, and the update puts detalimogene in the range of the most efficacious therapies, removing the efficacy barrier, the firm says.

Raymond James

Outperform -> Strong Buy

upgrade

$23 -> $27

2025-11-11

Reason

Raymond James

Price Target

$23 -> $27

2025-11-11

upgrade

Outperform -> Strong Buy

Reason

Raymond James upgraded enGene to Strong Buy from Outperform with a price target of $27, up from $23.

Raymond James

Sean McCutcheon

Outperform -> Strong Buy

upgrade

$23 -> $27

2025-11-11

Reason

Raymond James

Sean McCutcheon

Price Target

$23 -> $27

2025-11-11

upgrade

Outperform -> Strong Buy

Reason

Raymond James analyst Sean McCutcheon upgraded enGene to Strong Buy from Outperform with a price target of $27, up from $23, after the company disclosed an interim update from the pivotal cohort in their Phase 2 LEGEND study, comprised of patients with high-risk BCG unresponsive non-muscle invasive bladder cancer treated with detalimogene. The company included more patients in the analysis than anticipated, which the firm sees having a positive read on the rate of enrollment and on execution, notes the analyst, who did not modify revenue projections but cites "the substantial market opportunity" within NMIBC, particularly at community urology clinics, with efficacy approaching cretostimogene.

Valuation Metrics

The current forward P/E ratio for enGene Holdings Inc (ENGN.O) is -3.37, compared to its 5-year average forward P/E of -3.04. For a more detailed relative valuation and DCF analysis to assess enGene Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.04

Current PE

-3.37

Overvalued PE

-0.10

Undervalued PE

-5.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.07

Current EV/EBITDA

-2.77

Overvalued EV/EBITDA

1.28

Undervalued EV/EBITDA

-5.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ENGN News & Events

Events Timeline

No data

News

9.0

12-02Newsfilter

enGene Selected for FDA CDRP Program to Accelerate Drug Development

4.0

11-12Benzinga

Oppenheimer Affirms Outperform Rating for enGene Holdings and Increases Price Target to $33

9.0

11-11TipRanks

Reasons Behind the Surge in enGene Holdings Stock Today

People Also Watch

Frequently Asked Questions

What is enGene Holdings Inc (ENGN) stock price today?

The current price of ENGN is 8.475 USD — it has increased 0.18 % in the last trading day.

What is enGene Holdings Inc (ENGN)'s business?

enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

What is the price predicton of ENGN Stock?

What is enGene Holdings Inc (ENGN)'s revenue for the last quarter?

enGene Holdings Inc revenue for the last quarter amounts to -29.95M USD, increased 78.69 % YoY.

What is enGene Holdings Inc (ENGN)'s earnings per share (EPS) for the last quarter?

enGene Holdings Inc. EPS for the last quarter amounts to -26338000.00 USD, increased 266.67 % YoY.

What changes have occurred in the market's expectations for enGene Holdings Inc (ENGN)'s fundamentals?

How many employees does enGene Holdings Inc (ENGN). have?

enGene Holdings Inc (ENGN) has 56 emplpoyees as of December 15 2025.

What is enGene Holdings Inc (ENGN) market cap?

Today ENGN has the market capitalization of 546.33M USD.